In early‐phase studies, responses of CRC to PD‐1/PD‐L1 inhibitors were not promising.60 No objective response was seen in patients treated with PD‐1 inhibitors (0/19)49 or PD‐L1 inhibitors (0/16). This evidence concerns the gene PDCD1 and colorectal carcinoma.